Vaxart To Meet With FDA In Mid-2024 To Evaluate Clinical Data And Discuss Next Steps For Its Norovirus Program; Anticipates Cash Runway Into Late Q4 Of 2024
Vaxart To Meet With FDA In Mid-2024 To Evaluate Clinical Data And Discuss Next Steps For Its Norovirus Program; Anticipates Cash Runway Into Late Q4 Of 2024
These data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge study. Expects to initiate Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024.
這些數據將爲潛在的下一步行動提供信息，例如可能進行2b期研究和可能的GII.4挑戰研究。預計最早將在2024年第二季度啓動2b期研究，評估Vaxart的口服藥丸XBB COVID-19 疫苗與批准的mRNA疫苗比較對比。
Cash, cash equivalents and investments totaled $36.7 million as of March 31, 2024. The Company did not receive any cash payments from BARDA in the first quarter of 2024. Currently, Vaxart anticipates cash runway into late fourth quarter of 2024.
截至2024年3月31日，現金、現金等價物和投資總額爲3670萬美元。該公司在2024年第一季度沒有收到BARDA的任何現金付款。目前，Vaxart預計現金流將持續到2024年第四季度末。
譯文內容由第三人軟體翻譯。